Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Go back to Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

February 1, 2021 2:07 PM EST

- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications -

- Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT -

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for... More